Anixa Biosciences, Inc. (ANIX)
3.625
-0.08
(-2.29%)
USD |
NASDAQ |
Aug 24, 16:00
3.62
0.00 (0.00%)
After-Hours: 20:00
Anixa Biosciences Enterprise Value : 111.10M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 111.10M |
| August 20, 2026 | 107.03M |
| August 19, 2026 | 111.10M |
| August 18, 2026 | 101.60M |
| August 17, 2026 | 103.64M |
| August 14, 2026 | 93.12M |
| August 13, 2026 | 93.80M |
| August 12, 2026 | 94.82M |
| August 11, 2026 | 94.48M |
| August 10, 2026 | 95.50M |
| August 07, 2026 | 101.26M |
| August 06, 2026 | 101.60M |
| August 05, 2026 | 100.92M |
| August 04, 2026 | 100.92M |
| August 03, 2026 | 100.92M |
| July 31, 2026 | 101.26M |
| July 30, 2026 | 106.01M |
| July 29, 2026 | 103.30M |
| July 28, 2026 | 104.66M |
| July 27, 2026 | 102.62M |
| July 24, 2026 | 110.76M |
| July 23, 2026 | 112.46M |
| July 22, 2026 | 104.66M |
| July 21, 2026 | 106.01M |
| July 20, 2026 | 102.62M |
| Date | Value |
|---|---|
| July 17, 2026 | 100.58M |
| July 16, 2026 | 97.87M |
| July 15, 2026 | 103.98M |
| July 14, 2026 | 93.46M |
| July 13, 2026 | 89.05M |
| July 10, 2026 | 89.05M |
| July 09, 2026 | 94.48M |
| July 08, 2026 | 90.75M |
| July 07, 2026 | 85.66M |
| July 06, 2026 | 88.71M |
| July 02, 2026 | 96.17M |
| July 01, 2026 | 91.76M |
| June 30, 2026 | 80.23M |
| June 29, 2026 | 81.93M |
| June 26, 2026 | 79.89M |
| June 25, 2026 | 74.12M |
| June 24, 2026 | 78.20M |
| June 23, 2026 | 78.87M |
| June 22, 2026 | 79.21M |
| June 18, 2026 | 83.96M |
| June 17, 2026 | 76.50M |
| June 16, 2026 | 73.79M |
| June 15, 2026 | 69.38M |
| June 12, 2026 | 69.04M |
| June 11, 2026 | 69.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
| Sarepta Therapeutics, Inc. | 2.242B |
| Vicapsys Life Sciences, Inc. | 47.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.536M |
| Total Expenses (Quarterly) | 2.516M |
| EPS Diluted (Quarterly) | -0.0749 |
| Earnings Yield | -8.36% |
| Normalized Earnings Yield | -8.364 |